Tesamorelin — 5mg

Description

Tesamorelin is a stabilized analogue of GHRH (growth hormone-releasing hormone) with a longer half-life than CJC-1295 No DAC. It binds GHRH receptors in the pituitary to stimulate GH release, which then acts on adipose tissue through IGF-1 dependent and independent pathways to specifically reduce visceral adipose tissue (VAT). FDA approval for VAT reduction in HIV-associated lipodystrophy established the mechanistic proof: tesamorelin selectively mobilizes visceral fat even in the context of overall metabolic dysfunction.

Visceral fat — the fat stored around the organs, not subcutaneously — is hormonally active adipose tissue that produces inflammatory cytokines, estrogen (via aromatase), and insulin-disrupting signals. In perimenopausal women, estrogen withdrawal drives preferential VAT accumulation. Tesamorelin’s specific efficacy against VAT makes it directly relevant to this pattern — it addresses the fat compartment that both drives metabolic risk and is most resistant to caloric restriction. Clinical studies show 15–20% reduction in VAT volume over 26–52 weeks.

Female-calibrated dosing: 1–2mg subcutaneously once daily, evening preferred. Women often respond at 1mg — begin there. Cycle 12–16 weeks. Monitor IGF-1 levels if running extended protocols. Best used when visceral fat is the primary concern, or layered with a GLP-1 agonist for combined appetite and fat-distribution effects.

Storage: Store lyophilized powder below -20°C. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 30 days.